Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with…
Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of…
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy…
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene…
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria…
TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000…
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough,…
CHICAGO, May 15, 2025 /PRNewswire/ -- The global AI In Life science Analytics Market is projected to be valued at USD 1.9…
Dark genome biotech RyboDyn deepens partnership with world-leading cancer immunotherapy center to validate novel oncology targets and advance first-in-class therapies…